Asian Spectator

ACN Newswire Business

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

  • Written by ACN Newswire - Press Releases

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

TOKYO, Oct 16, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in China by the National Medical Products Administration.

The submission covering monotherapy for partial-onset seizures was based on subgroup analysis estimating monotherapy safety and efficacy within clinical studies of the combination therapy (Study 304, 305, 306, and 335) conducted globally including the United States, Europe and China on patients ages 12 years and older with partial-onset seizures (with or without secondarily generalized seizures). Additionally, results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea on untreated epilepsy patients ages 12 years to 74 years old with partial-onset seizures (with or without secondarily generalized seizures) were submitted as supplementary safety and efficacy data.

The submission covering partial-onset seizures in pediatric patients was based on the results of a Phase III clinical study (Study 311) of Fycompa as adjunctive therapy conducted globally on pediatric patients (ages 4 to less than 12 years) with inadequately controlled partial-onset seizures or primary generalized tonic-clonic seizures.

In China, it is estimated that there are approximately 9 million patients with epilepsy, and although onset occurs at any age, onset is most common in people aged 18 and younger and the elderly. As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs1, this is a disease with significant unmet medical needs.

Fycompa is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba ResearchLaboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Fycompa has been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.

Eisai considers neurology, including epilepsy, a therapeutic area of focus. With the acceptance of these additional applications regarding Fycompa in China, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy across the world. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

For more information, visit https://www.eisai.com/news/2020/pdf/enews202064pdf.pdf.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

LTI USD revenues grow 11.2% YoY; Net Profit up 26.7% YoY

MUMBAI, India, Oct. 21, 2020 /PRNewswire-AsiaNet/ -- Larsen & Toubro Infotech (BSE code: 540005) (NSE: LTI), a global technology consulting and digital solutions company, announced its Q...

Detect-It LLC Launches Coder-Free Neural Net Life Cycle Manage...

OAK PARK, Michigan, Oct. 21, 2020 /PRNewswire-AsiaNet/ -- - Artificial Intelligence for everyone to make life easier, safer and more productive.Detect-It LLC today launched its smart softwar...

Afrobeats Singer, Davido, Unveils the Routes of Inspiration Be...

LONDON, Oct. 21, 2020 /PRNewswire-AsiaNet/ -- - Davido gives a glimpse into his creative process behind the making of his most recent album 'A Better Time', as part of the Routes of Inspirat...

Aberdeen's green stone coating expands into USA

TAIPEI, TAIWAN - Media OutReach - 20 October 2020 - The faux stone coating for buildings, a green product developed and manufactured by Aberdeen, has built a solid market base in ASEAN ...

Planful Welcomes Kimberly Simms as Chief Customer Officer

REDWOOD CITY, California, Oct. 20, 2020 /PRNewswire-AsiaNet/ -- -- With Extensive Industry Experience and Customer Success Program Expertise, Simms Will Be a Significant Asset to Planful and...

Artprice by Artmarket.com: Condition of the Street Art market ...

PARIS, Oct. 20, 2020 /PRNewswire-AsiaNet/ -- At its online sale on 28 May 2020, Phillips sold Banksy's lot Happy Choppers (2003) for $39,000. That may not seem surprising until you take into...

Magazine

Australian startup CareApp receives funding injection to expand app

Australian based startup CareApp has recently raised over $500,000 in funding including $250,000 provided by the South Australian State Government to rapidly expand and scale up their smartphone...

Shaparency launches to enable businesses to go fully digital

New venture developed for post-Covid-19 corporate landscape London-based start-up Shaparency, which has been established in response to the business conditions resulting from Covid-19, announces ...

Specops Significant Cyber Attacks

The prevalence and severity of cyber attacks are increasing at an alarming rate every year. So much so, that statistics from Cybersecurity Ventures estimate that cybercrime will cost the global ...

Writers Wanted



News Co Media Group

Content & Technology Connecting Global Audiences

More Information - Less Opinion